Literature DB >> 6490826

Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories.

R N Jones, C Thornsberry, A L Barry, L Ayers, S Brown, J Daniel, P C Fuchs, T L Gavan, E H Gerlach, J M Matsen.   

Abstract

HR810 is a new, very broad-spectrum cephalosporin with significant activity against members of the family Enterobacteriaceae, pseudomonads, gram-positive cocci, and anaerobes that is generally greater than the third-generation cephalosporins (99.6% of 4,128 clinical facultative enteric isolates were inhibited by less than or equal to 8.0 micrograms of HR810 per ml). Tests and statistical methods to establish in vitro antimicrobial susceptibility test criteria favor tentative breakpoints of greater than or equal to 18 mm (less than or equal to 8.0 micrograms/ml) as susceptible and less than or equal to 14 mm (greater than or equal to 32 micrograms/ml) as resistant. This provides a 93.7 to 98.3% absolute interpretive accuracy. Several preliminary ranges for zone sizes obtained with quality control organisms are proposed for the 30-micrograms HR810 disk diffusion test used during the clinical trials.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6490826      PMCID: PMC271340          DOI: 10.1128/jcm.20.3.409-412.1984

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

2.  Susceptibility of gram-positive aerobic cocci to the new cephalosporin HR 810.

Authors:  A Bauernfeind
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

3.  Relation between beta-lactamase production and antimicrobial activity: comparison of the new compound HR 810 with cefotaxime.

Authors:  W Cullmann; W Opferkuch; M Stieglitz
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

4.  HR 810, a cephalosporin with low affinity for Enterobacter cloacae beta-lactamase.

Authors:  R M Tolxdorff-Neutzling; B Wiedemann
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

5.  Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.

Authors:  T L Gavan; R N Jones; A L Barry; P C Fuchs; E H Gerlach; J M Matsen; L B Reller; C Thornsberry; L D Thrupp
Journal:  J Clin Microbiol       Date:  1981-07       Impact factor: 5.948

6.  Transferable multiple antibiotic resistance in Haemophilus influenzae.

Authors:  V O Rotimi; D C Turk
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

Review 7.  Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.

Authors:  R N Jones; C Thornsberry
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

Review 8.  Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics.

Authors:  R N Jones; A L Barry
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

9.  HR 810, a new parenteral cephalosporin with a broad antibacterial spectrum.

Authors:  G Seibert; N Klesel; M Limbert; E Schrinner; K Seeger; I Winkler; R Lattrell; J Blumbach; W Dürckheimer; K Fleischmann
Journal:  Arzneimittelforschung       Date:  1983

10.  In vitro activity of HR 810, a new broad-spectrum cephalosporin.

Authors:  K Machka; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

View more
  9 in total

1.  Community-acquired Acinetobacter baumannii bacteremia in adult patients in Taiwan.

Authors:  Jann-Tay Wang; Lawrence Clifford McDonald; Shan-Chwen Chang; Monto Ho
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

2.  Interpretive criteria for the agar diffusion susceptibility test with ofloxacin.

Authors:  H Grimm
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin.

Authors:  P C Fuchs; R N Jones; A L Barry; C Thornsberry
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

4.  Microanalytical high-performance liquid chromatography assay for cefpirome (HR 810) in serum.

Authors:  C P Turley; G L Kearns; R F Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

5.  Antimicrobial activity of HR810 against 419 strict anaerobic bacteria.

Authors:  R N Jones; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

6.  Effects of blood medium supplements on activities of newer cephalosporins tested against enterococci.

Authors:  B J Buschelman; R N Jones; M J Bale
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

7.  Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

8.  Bactericidal activity of cefpirome (HR 810) against 513 gram-negative bacteria isolated from blood of septicemic patients.

Authors:  M G Bergeron; M Bernier
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

9.  New Stability Indicating RP-HPLC Method for the Estimation of Cefpirome Sulphate in Bulk and Pharmaceutical Dosage Forms.

Authors:  Kareti Srinivasa Rao; Keshar Nargesh Kumar; Datta Joydeep
Journal:  Sci Pharm       Date:  2011-08-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.